German drug giant Boehringer Ingelheim opens venture capital office in Cambridge - Boston Business Journal
NBE Therapeutics - NBE Therapeutics
Investors – Tacalyx GmbH
Boehringer Ingelheim doubles down on venture funding input
Boehringer Ingelheim Venture Fund | Our Team
Boehringer Ingelheim Venture Fund | Our Team
Adam Kundzewicz, PhD - Executive Director, Venture Fund - Boehringer Ingelheim | LinkedIn
HKSTP and Boehringer Ingelheim Venture Fund launch co-incubation programme to fast-track R&D in infectious diseases and immunology | The Financial Express
Boehringer Ingelheim Venture Fund | About us
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund Investor Profile: Portfolio & Exits | PitchBook
Boehringer Ingelheim Venture Fund investor portfolio, rounds & team | Dealroom.co
Boehringer Ingelheim Ups Venture Fund to €250M | BioSpace
Boehringer backs AI-powered drug discovery startup ArrePath | HealthCare Middle East & Africa Magazine
Boehringer Ingelheim Venture Fund - News, Articles, Whitepapers - Drug Target Review
Boehringer Ingelheim y Vira Therapeutics inician una colaboración en terapia viral oncolítica - El Global
Boehringer Ingelheim rounds up pharma allies to put up a joint venture to fight AMR | HealthCare Middle East & Africa Magazine
Boehringer Ingelheim Venture Fund and PPF Group Close a US $ 22M Series C Financing for NBE-Therapeutics | ADC Review
Boehringer Ingelheim Venture Fund – ABALOS THERAPEUTICS
Eyevensys Announces an Equity Investment by Boehringer Ingelheim Venture Fund | Technology Networks
Boehringer Ingelheim Venture Fund | Our Team
Our Venture Fund on the search for groundbreaking trends | Boehringer Ingelheim
